Overview

A Study of K-645 in the Treatment of Multiple Migraine Attacks

Status:
RECRUITING
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.
Phase:
PHASE2
Details
Lead Sponsor:
Kallyope Inc.